Cargando…

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy

Through whole-transcriptome profiling of HER2+ breast carcinomas (BCs), we previously showed that those sensitive to trastuzumab are addicted to this oncoprotein and are enriched in immune pathways, raising the hypothesis that HER2 itself regulates immune cell recruitment. In the present study we in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Triulzi, Tiziana, Forte, Luca, Regondi, Viola, Di Modica, Martina, Ghirelli, Cristina, Carcangiu, Maria Luisa, Sfondrini, Lucia, Balsari, Andrea, Tagliabue, Elda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287794/ https://www.ncbi.nlm.nih.gov/pubmed/30546951 http://dx.doi.org/10.1080/2162402X.2018.1512942

Ejemplares similares

HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer
por: Triulzi, Tiziana, et al.
Publicado: (2022)

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
por: Di Modica, Martina, et al.
Publicado: (2015)

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
por: Triulzi, Tiziana, et al.
Publicado: (2018)

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
por: Di Modica, Martina, et al.
Publicado: (2022)

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
por: Di Modica, Martina, et al.
Publicado: (2017)

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
por: Triulzi, Tiziana, et al.
Publicado: (2015)

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
por: Rybinska, Ilona, et al.
Publicado: (2020)

Local Administration of Caloric Restriction Mimetics to Promote the Immune Control of Lung Metastases
por: Le Noci, Valentino, et al.
Publicado: (2019)

Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors
por: Lucci, Maria Antonietta, et al.
Publicado: (2010)

Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors
por: Agresti, Roberto, et al.
Publicado: (2019)

Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer
por: Tiwari, Saumya, et al.
Publicado: (2020)

The Emerging Role of the Microbiota in Breast Cancer Progression
por: Bernardo, Giancarla, et al.
Publicado: (2023)

Exploiting poly(I:C) to induce cancer cell apoptosis
por: Bianchi, Francesca, et al.
Publicado: (2017)

Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress
por: Triulzi, Tiziana, et al.
Publicado: (2013)

The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy
por: Sommariva, Michele, et al.
Publicado: (2020)

TLR3 Expression Induces Apoptosis in Human Non-Small-Cell Lung Cancer
por: Bianchi, Francesca, et al.
Publicado: (2020)

The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer
por: Forte, Luca, et al.
Publicado: (2018)

Rescue of HER-2-positive breast carcinoma cells from dormancy by growth factors produced during wound healing
por: Agresti, R, et al.
Publicado: (2001)

Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors
por: Giussani, Marta, et al.
Publicado: (2019)

Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences
por: Rybinska, Ilona, et al.
Publicado: (2021)

Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity
por: Bianchi, Francesca, et al.
Publicado: (2021)

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers
por: Turdo, Federica, et al.
Publicado: (2016)

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts
por: De Cesare, Michelandrea, et al.
Publicado: (2016)

Adipocytes in Breast Cancer, the Thick and the Thin
por: Rybinska, Ilona, et al.
Publicado: (2020)

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
por: Camelliti, Simone, et al.
Publicado: (2020)

The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles
por: Indino, Serena, et al.
Publicado: (2022)

Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer
por: Song, Patrick N., et al.
Publicado: (2022)

ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab
por: Agnolon, Valentina, et al.
Publicado: (2020)

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
por: Baker, Jennifer Hazel Elizabeth, et al.
Publicado: (2018)

Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate “altered” cells?
por: Sommariva, Michele, et al.
Publicado: (2012)

High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors
por: Sommariva, Michele, et al.
Publicado: (2013)

“Omics” and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas
por: Tagliabue, Elda, et al.
Publicado: (2014)

Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression
por: Le Noci, Valentino, et al.
Publicado: (2021)

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
por: Castagnoli, Lorenzo, et al.
Publicado: (2019)

Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients
por: Bianchi, Francesca, et al.
Publicado: (2019)

Identification of HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviours
por: Casalini, P, et al.
Publicado: (2001)

Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers
por: Feng, Weiwei, et al.
Publicado: (2010)

Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model
por: Rossini, Anna, et al.
Publicado: (2012)

Live or Heat-Killed Lactobacillus rhamnosus Aerosolization Decreases Adenomatous Lung Cancer Development in a Mouse Carcinogen-Induced Tumor Model
por: Le Noci, Valentino, et al.
Publicado: (2022)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_32nj2u4t61bj65cll5ru3nspmn